M.E. Allison & CO. Inc. Has $638,000 Holdings in Pfizer Inc. (NYSE:PFE)

M.E. Allison & CO. Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 54.3% in the first quarter, HoldingsChannel reports. The fund owned 25,162 shares of the biopharmaceutical company’s stock after buying an additional 8,851 shares during the quarter. M.E. Allison & CO. Inc.’s holdings in Pfizer were worth $638,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PFE. Tallon Kerry Patrick purchased a new stake in shares of Pfizer during the 4th quarter worth about $509,000. Brighton Jones LLC raised its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. Banque Pictet & Cie SA raised its stake in shares of Pfizer by 9.6% during the 4th quarter. Banque Pictet & Cie SA now owns 15,108 shares of the biopharmaceutical company’s stock worth $401,000 after purchasing an additional 1,318 shares in the last quarter. Finally, TigerOak Management L.L.C. purchased a new stake in shares of Pfizer during the 4th quarter worth about $837,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE stock opened at $24.51 on Monday. The stock’s fifty day simple moving average is $23.06 and its 200 day simple moving average is $24.95. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market cap of $139.35 billion, a price-to-earnings ratio of 17.38, a P/E/G ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.82 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a $0.43 dividend. The ex-dividend date was Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.02%. Pfizer’s payout ratio is 124.64%.

Analyst Ratings Changes

A number of research analysts recently weighed in on PFE shares. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective on the stock. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.